Perrigo announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Desoximetasone Topical Spray, 0.25%, the first generic of Taro‘s Topicort Spray, 0.25%.
Topicort is a corticosteroid topical spray that is indicated for the treatment of plaque psoriasis in patients aged ≥18 years. Although the exact mechanism of action of corticosteroids in psoriasis is unknown, they are known to influence cellular signaling, immune function, inflammation and protein regulation.
Desoximetasone Topical Spray will be available in a 0.25% strength spray pump.
For more information call (866) 634-9120 or visit Perrigo.com.